Allakos Inc. (NASDAQ:ALLK) CFO Harlan Baird Radford Sells 87,064 Shares

Allakos Inc. (NASDAQ:ALLK) CFO Harlan Baird Radford sold 87,064 shares of Allakos stock in a transaction on Friday, June 28th. The stock was sold at an average price of $1.01, for a total value of $87,934.64. Following the completion of the transaction, the chief financial officer now owns 204,390 shares in the company, valued at $206,433.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Allakos Trading Down 9.6 %

Shares of ALLK stock opened at $0.76 on Friday. Allakos Inc. has a 1-year low of $0.76 and a 1-year high of $5.64. The company has a market capitalization of $67.29 million, a price-to-earnings ratio of -0.31 and a beta of 0.88. The stock’s fifty day simple moving average is $1.18 and its 200-day simple moving average is $1.47.

Allakos (NASDAQ:ALLK) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.09). On average, sell-side analysts predict that Allakos Inc. will post -1.24 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. JMP Securities restated a “market outperform” rating and issued a $3.00 target price on shares of Allakos in a report on Wednesday, June 26th. Cantor Fitzgerald restated a “neutral” rating on shares of Allakos in a report on Thursday, June 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Allakos currently has a consensus rating of “Hold” and a consensus price target of $1.83.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ALLK. Sectoral Asset Management Inc. grew its holdings in shares of Allakos by 77.3% during the third quarter. Sectoral Asset Management Inc. now owns 770,132 shares of the company’s stock valued at $1,748,000 after buying an additional 335,822 shares in the last quarter. Redmile Group LLC grew its holdings in shares of Allakos by 81.1% during the third quarter. Redmile Group LLC now owns 4,135,061 shares of the company’s stock valued at $9,387,000 after buying an additional 1,851,467 shares in the last quarter. Aristides Capital LLC purchased a new position in shares of Allakos during the fourth quarter valued at $153,000. Pennant Investors LP acquired a new stake in Allakos during the fourth quarter valued at $508,000. Finally, BNP Paribas Financial Markets boosted its position in Allakos by 1,041.1% during the first quarter. BNP Paribas Financial Markets now owns 205,663 shares of the company’s stock valued at $259,000 after purchasing an additional 187,640 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.